TY - JOUR
T1 - FBPA PET in boron neutron capture therapy for cancer
T2 - Prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model
AU - Hanaoka, Kohei
AU - Watabe, Tadashi
AU - Naka, Sadahiro
AU - Kanai, Yasukazu
AU - Ikeda, Hayato
AU - Horitsugi, Genki
AU - Kato, Hiroki
AU - Isohashi, Kayako
AU - Shimosegawa, Eku
AU - Hatazawa, Jun
N1 - Funding Information:
This study was supported by the KAKENHI Grant-in-Aid for Scientific Research (S) (No. 24229008) and Molecular Imaging Research Strategic Program, and Grant (No. 10048012 and No. 24591758) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Publisher Copyright:
© 2014, Hanaoka et al.; licensee Springer.
PY - 2014/12/20
Y1 - 2014/12/20
N2 - Background: Boron neutron capture therapy (BNCT) is a molecular radiation treatment based on the 10B (n, α) 7Li nuclear reaction in cancer cells, in which delivery of 10B by 4-borono-phenylalanine conjugated with fructose (BPA-fr) to the cancer cells is of critical importance. The PET tracer 4-borono-2-18 F-fluoro-phenylalanine (FBPA) has been used to predict the accumulation of BPA-fr before BNCT. However, because of the difference in chemical structure between BPA-fr and FBPA and the difference in the dose administered between BPA-fr (therapeutic dose) and FBPA (tracer dose), the predictive value of FBPA PET for BPA-fr accumulation in the tumor and normal tissues is not yet clearly proven. We conducted this study to validate FBPA PET as a useful test to predict the accumulation of BPA-fr in the tumor and normal tissues before BNCT. Methods: RGC-6 rat glioma cells (1.9 × 107) were implanted subcutaneously in seven male F344 rats. On day 20 after the tumor implantation, dynamic PET scan was performed on four rats after injection of FBPA for 1 h. Whole-body PET/CT was performed 1 h after intravenous injection of the FBPA solution (30.5 ± 0.7 MBq, 1.69 ± 1.21 mg/kg). PET accumulation of FBPA in the tumor tissue and various normal tissues was estimated as a percentage of the injected dose per gram (%ID/g). One hour after the PET/CT scan, BPA-fructose (167.32 ± 18.65 mg/kg) was injected intravenously, and the rats were dissected 1 h after the BPA-fr injection. The absolute concentration of 10B in the autopsied tissues and blood was measured by inductively coupled plasma optical emission spectrometry (ICP-OES). Results: The highest absolute concentration of 10B determined by ICP-OES was found in the kidney (4.34 ± 0.84 %ID/g), followed by the pancreas (2.73 ± 0.63 %ID/g), and the tumor (1.44 ± 0.44 %ID/g). A significant positive correlation was found between the accumulation levels of BPA-fr and FBPA (r = 0.91, p < 0.05). Conclusions: FBPA PET can reliably predict accumulation of BPA-fr in the tumor as well as normal tissues.
AB - Background: Boron neutron capture therapy (BNCT) is a molecular radiation treatment based on the 10B (n, α) 7Li nuclear reaction in cancer cells, in which delivery of 10B by 4-borono-phenylalanine conjugated with fructose (BPA-fr) to the cancer cells is of critical importance. The PET tracer 4-borono-2-18 F-fluoro-phenylalanine (FBPA) has been used to predict the accumulation of BPA-fr before BNCT. However, because of the difference in chemical structure between BPA-fr and FBPA and the difference in the dose administered between BPA-fr (therapeutic dose) and FBPA (tracer dose), the predictive value of FBPA PET for BPA-fr accumulation in the tumor and normal tissues is not yet clearly proven. We conducted this study to validate FBPA PET as a useful test to predict the accumulation of BPA-fr in the tumor and normal tissues before BNCT. Methods: RGC-6 rat glioma cells (1.9 × 107) were implanted subcutaneously in seven male F344 rats. On day 20 after the tumor implantation, dynamic PET scan was performed on four rats after injection of FBPA for 1 h. Whole-body PET/CT was performed 1 h after intravenous injection of the FBPA solution (30.5 ± 0.7 MBq, 1.69 ± 1.21 mg/kg). PET accumulation of FBPA in the tumor tissue and various normal tissues was estimated as a percentage of the injected dose per gram (%ID/g). One hour after the PET/CT scan, BPA-fructose (167.32 ± 18.65 mg/kg) was injected intravenously, and the rats were dissected 1 h after the BPA-fr injection. The absolute concentration of 10B in the autopsied tissues and blood was measured by inductively coupled plasma optical emission spectrometry (ICP-OES). Results: The highest absolute concentration of 10B determined by ICP-OES was found in the kidney (4.34 ± 0.84 %ID/g), followed by the pancreas (2.73 ± 0.63 %ID/g), and the tumor (1.44 ± 0.44 %ID/g). A significant positive correlation was found between the accumulation levels of BPA-fr and FBPA (r = 0.91, p < 0.05). Conclusions: FBPA PET can reliably predict accumulation of BPA-fr in the tumor as well as normal tissues.
KW - BPA-fr
KW - Boron concentration
KW - Boron nuclear capture therapy
KW - FBPA
UR - http://www.scopus.com/inward/record.url?scp=84938089638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938089638&partnerID=8YFLogxK
U2 - 10.1186/s13550-014-0070-2
DO - 10.1186/s13550-014-0070-2
M3 - Article
AN - SCOPUS:84938089638
VL - 4
JO - EJNMMI Research
JF - EJNMMI Research
SN - 2191-219X
IS - 1
M1 - 70
ER -
